Open Orphan PLC (LON:ORPH), the rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials has noted its recent share price movement and press speculation regarding UK government-funded Coronavirus human challenge studies.
In a brief statement, the company confirmed that it is in advanced negotiation with the government and other partners for a Coronavirus challenge study in the UK.
READ: Open Orphan says Venn Life Sciences subsidiary secures important new contract to support major European pharma company
The group said: "While negotiations continue, it is expected that in the event that a contract is agreed revenue will be in excess of £7mln, being the approximate anticipated revenue for a Coronavirus challenge study as indicated by Open Orphan on May 22, 2020."
However, it added, there can be no certainty that these discussions will lead to a new contract until final negotiations are concluded.
The company said it will update the market in due course as appropriate.
In morning trade on Thursday, Open Orphan shares were 6.4% lower at 17.55p.